Bavarian Nordic’s announcement that Paul Chaplin will step down as CEO has marked the latest high-profile change at a pharmaceutical company in 2026. Chaplin, who has been at the helm of the Danish vaccine specialist since 2014, is leaving for personal reasons. Over his tenure, he has overseen Bavarian’s development from a small research-based company to a publicly listed vaccine manufacturer with approved products in multiple regions. Chaplin will continue to serve as CEO for the remainder of 2026, unl ...